The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPURE.L Regulatory News (PURE)

  • There is currently no data for PURE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FDA 'No Objection' ruling on new product

21 Jul 2010 07:00

RNS Number : 6497P
PureCircle Limited
21 July 2010
 



PureCircle receives FDA GRAS "No Objection" for new SG95 stevia product

 

PureCircle (LSE: PURE), the world's leading producer of high purity stevia products, is pleased to announce that the US Food and Drug Administration (FDA) has issued a No Objection letter for the use of PureCircle's SG95 product as a Food and Beverage ingredient in the USA. This will enable PureCircle to offer a wider and more flexible array of stevia solutions, helping to further accelerate stevia adoption in the important USA market.

 

PureCircle's high purity SG95 product is a further example of the company's leadership in innovation. Along with seven previously approved steviol glycosides, SG95 includes two new steviol gylcosides, Rebaudioside D and Rebaudioside F, both of which are receiving GRAS No Objection for the first time. The new high purity sweetener delivers great taste and consistency as well as pricing well below sugar. The product is ideally suited for applications formulated with both sugar and SG95 to achieve a low cost solution to partial sugar and calorie reduction and provide further incentive to application development. Together with PureCircle's successful high purity Reb A 97, SG95 will provide customers with an expanded range of options to improve products across their portfolios. With GRAS affirmation, PureCircle is prepared for immediate commercialisation of SG95.

 

Magomet Malsagov, CEO and Managing Director of PureCircle, said: "The launch of SG95 is a very exciting development for PureCircle in the United States with considerable future potential in global markets. Expanded use of sweet glycosides from the stevia plant in a highly consistent blend provides both formulation and economic benefits to our customers. Our Reb A 97 continues to play a major role in our portfolio particularly as our investments yield continued efficiencies that will be shared with our customers. Now SG95 will provide an additional compelling product in many applications. We are proud to continue to be at the forefront of innovation to help mainstream a better sweet choice for consumers. "

 

For more information:

PureCircle Limited (www.purecircle.com)

Jason Hecker, Group Marketing Director

(847) 630-0374

Magomet Malsagov, CEO

+60 1 2388 8049

William Mitchell, CFO 

+44 7974 005 163 

Westport Communications

+44 20 7065 2690

Alan Frame

alan@westportcomms.com

Jeanette Bishop

RFC Corporate Finance Ltd

+61 8 9480 2500 

Stephen Allen

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REAPGURPMUPUGQU
Date   Source Headline
29th Oct 20097:00 amRNSProduct Launch
27th Oct 200912:35 pmRNSHolding(s) in Company
21st Oct 20097:00 amRNSPureCircle and PepsiCo to receive Scientific Excel
20th Oct 20097:00 amRNSProduct Launch
15th Oct 200910:00 amRNSTrading Statement
8th Oct 20097:00 amRNSDirector Declaration
23rd Sep 20097:00 amRNSFinal Results
8th Sep 20098:32 amRNSStatement re Approval
4th Sep 20093:00 pmRNSStatement re Shareholding
2nd Sep 200910:10 amRNSChange of Adviser
8th Jul 20097:00 amRNSTrading Update
15th Jun 20098:41 amRNSNotification of a Major Interest
27th Apr 20097:02 amRNSCompletion of Extract Plant Complex
1st Apr 20097:00 amRNSDealings in Shares
5th Mar 20099:20 amRNSDirector's Dealing
4th Mar 20097:00 amRNSHalf Yearly Report
29th Jan 20097:00 amRNSSENIOR INTERNATIONAL SALES TEAM APPOINTMENT
19th Jan 20097:00 amRNSAppointment
13th Jan 20097:00 amRNSAppointment of Head of PureCircle USA
12th Jan 20097:09 amRNSNotice of Results
6th Jan 20097:00 amRNSStrategic Global Collaboration
5th Jan 20097:00 amRNSDirector Dealings
18th Dec 20087:00 amRNSRegulatory Approval
24th Nov 20087:51 amRNSExecutive Management Appointments
10th Nov 20087:55 amRNSIssuance of Options
7th Nov 20089:51 amRNSExercise of Options
17th Oct 20083:05 pmRNSDealings in shares
15th Oct 20087:00 amRNSFinal Results
13th Oct 200812:58 pmRNSBoard Change
10th Oct 20089:44 amRNSApproval Announced
22nd Aug 20087:00 amRNSRevised Results Day
20th Aug 20088:42 amRNSBoard Appointment
31st Jul 20083:42 pmRNSMajor contract win
21st Jul 20088:45 amRNSNotice of Interim Results
2nd Jul 20088:10 amRNSRe Share Holdings
2nd Jul 20087:03 amRNSDirector's Dealings
1st Jul 20081:08 pmRNSStrategic Partnership
16th Jun 20088:34 amRNSLong Term Incentive Plan
2nd Jun 20089:27 amRNSAGM and Board appointments
2nd Jun 20087:00 amRNSDealings in Shares
20th May 20089:08 amRNSCompletion of aquisition and
9th May 20088:39 amRNSNotice of AGM
7th May 20087:00 amRNSAppointment
6th May 20088:33 amRNSKenya Joint Venture
22nd Apr 200811:19 amRNSInvestor Presentation
7th Apr 20088:37 amRNSAcquisition
1st Apr 20087:01 amRNSFinal Results
31st Mar 20089:19 amRNSNotification re: results
10th Mar 20081:16 pmRNSResults Date
28th Feb 20088:43 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.